Occam Recruits David Moller as Chief Scientific Officer of Variant Bio
Variant Bio, a genomics-driven drug discovery company backed by Lux Capital, General Catalyst, Alta Partners, SoftBank, and Casdin Capital, announced David Moller, MD as Chief Scientific Officer.
In Moller, Variant captures a broadly gauged and versatile drug discovery and development leader with over two decades of experience presiding over R&D in both big pharma and biotech, including Eli Lilly and Merck. He brings with him a deep understanding of and facility for transmuting complex genetic insights into innovative therapeutic programs, a knowledge that will doubtlessly enable Variant to deliver on its substantial potential as a transformative genomics-based drug discovery and development organization.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.